An integrated ecosystem for healing at scale.

An integrated ecosystem for healing at scale.

Our company

Numinus is an integrated mental health company creating an ecosystem of health solutions to research, develop, and deliver safe, evidence-based, accessible psychedelic-assisted psychotherapy.

Numinus Bioscience is a Health Canada-licensed lab for psychedelic substance research, developing IP while offering analytics services for revenue generation.

Numinus R&D is developing psychedelic-assisted therapeutic protocols to embed in mainstream healthcare, led by medical leadership with global research and policy reform experience.

Numinus Health delivers treatments to patients through clinics and virtual services, for physical, mental, and emotional healing.

This trifecta of solutions positions Numinus at the forefront of psychedelics for healing and wellness.

First-mover licensing advantage for psychedelic research.

A history of firsts. Through the Bioscience lab, Numinus is the first public company in Canada to receive a licence to produce and extract psilocybin from mushrooms, and the first to complete a legal harvest of psilocybe mushrooms using this licence.

This first-mover advantage allows us to research and develop proprietary, standardized extraction methods, testing methods and product formulations—for use in R&D partnerships, contract research services, and clinical trials.

Numinus also possesses a dealer's licence from Health Canada to import, export, possess, test, and distribute MDMA, psilocybin, psilocin, DMT, and mescaline.

Lastly, Numinus holds a cannabis testing licence from Health Canada, allowing us to provide third-party analytics and testing services for revenue generation.

Together, through months and years of applications, these licenses have built a firm foundation on applied research, IP development, and R&D partnerships to complement and facilitate the activities at Numinus R&D and Numinus Health.

Leading through implementation science.

Health Canada has approved psilocybin-assisted therapy to treat anxiety in terminally ill patients, while psychedelic therapies have been designated breakthrough therapy* status in the U.S. by the FDA. Government support is anticipated to increase for pre-legalization access, although the therapies remain illegal in Canada.

Numinus addresses the current access hurdle by following an implementation science agenda, which applies research to real world contexts to support wider adoption and integration into mainstream healthcare.

Compassionate access is one such pathway that Numinus is pursuing, for psilocybin and MDMA.

This is an open-label study to meet the needs of patients who are ineligible for other trials. It is Health Canada's preferred means for manufacturers to provide patients with access to drugs that are not yet available on the market.

When approved and regulated, Numinus aims to make psychedelic-assisted psychotherapy accessible through a network of health centres that provide safe, controlled, and therapeutic environments in which patients can heal and become well.

* U.S. Food and Drug Administration (FDA) designation that expedites the development and review of drugs intended to treat a serious condition.

Our team

Numinus is led by scientific, medical and business leaders whose expertise spans international healthcare research, policy reform, regulatory affairs, capital markets, technology, and government relations.

This capable leadership manages a team of highly trained research and health care professionals, while maintaining a robust network of relationships with advisors, partners, and investors across North America and Europe.

Such synergy allows Numinus to drive financially-sustainable development and nimbly navigate this nascent industry.

Learn More